---
# System prepended metadata

title: Untitled

---

Monoclonal Antibody Therapy Market 2023-2030

The [[monoclonal antibody therapy](https://www.fortunebusinessinsights.com/monoclonal-antibody-therapy-market-102734 )] was an emerging and rapidly evolving field in medicine. Monoclonal antibodies (mAbs) are laboratory-made molecules designed to mimic the immune system's ability to fight off harmful pathogens, such as viruses or cancer cells.
Here are some key points about the monoclonal antibody therapy market as of September 2021:
1.	Market Growth: The monoclonal antibody therapy market was experiencing significant growth. Factors contributing to this growth included the development of new and improved mAb therapies, expanding applications in various disease areas, and increased investment in research and development.
2.	Cancer Therapy: mAbs were widely used in cancer treatment. They could target specific proteins on cancer cells, helping to stop their growth or trigger an immune response against them.
3.	Autoimmune Disorders: In autoimmune diseases, the immune system mistakenly attacks the body's own tissues. Monoclonal antibodies were developed to target specific components of the immune system to help manage these conditions.
4.	Infectious Diseases: The COVID-19 pandemic led to a surge in interest and development of monoclonal antibodies for the treatment of viral infections. Several mAb therapies were authorized for emergency use to treat COVID-19.
5.	Challenges: Despite the promise of monoclonal antibodies, there were challenges, including high production costs, potential for immunogenicity (the body's immune response against the mAb), and the need for specialized manufacturing facilities.
6.	Regulatory Approval: Obtaining regulatory approval for new monoclonal antibody therapies was a critical step in bringing these treatments to market. This process involved rigorous clinical trials and evaluation by regulatory agencies such as the FDA (U.S. Food and Drug Administration) and the EMA (European Medicines Agency).
The monoclonal antibody therapy size market key players are AbbVie Inc. (Illinois, United States), Merck & Co., Inc. (New Jersey, United States), F.Hoffmann-La Roche Ltd. (Basel, Switzerland), Bristol-Myers Squibb Company (New York, United States), Johnson & Johnson Services, Inc. (New Jersey, United States), Daiichi Sankyo Company, Limited (Tokyo, Japan), Novartis AG (Basel, Switzerland), Alexion Pharmaceuticals, Inc.  (Massachusetts, United States), Amgen Inc. (California, United States)
